Meritage Pharma Gets $22.5M

San Diego-based Meritage Pharma said Monday that it has raised $22.5M in a Series A venture funding for its specialty pharmaceuticals. The funding round came from Domain Associates, Latterell Venture Partner, and The Vertical Group. Meritage Pharma's initial product is targeted at treatment of allergic inflammation of the gastrointestinal tract, which the firm acquired by Verus Pharmaceuticals. The new firm is chaired by Cam L. Gardner, and headed by Malcolm R. Hill. Domain's Gradner and James C. Blair along with Latterell's Kenneth J. Widder are also on the company's board.